Company news
Celularity Inc. (NASDAQ:CELU) news
Every Celularity Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Celularity Announces Participation in Upcoming Investor Conferences
September 6, 2022
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
August 9, 2022
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
July 27, 2022
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
June 3, 2022
Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules
May 18, 2022
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 31, 2022
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
February 15, 2022
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
January 18, 2022
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
December 27, 2021
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
November 29, 2021
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
November 12, 2021
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
September 20, 2021
Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President
September 15, 2021
Celularity Reports Second Quarter 2021 Financial Results
August 16, 2021